Nasal foralumab for ALS safety and activity trial
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a nasal spray medication called foralumab to see if it is safe and affects inflammation in the brain for people with ALS. It may help by calming overactive immune cells in the nervous system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and have been diagnosed with ALS by a neurologist.
- You have had symptoms of weakness or muscle stiffness for no more than 24 months.
- A blood test showed a high level of a nerve damage marker (neurofilament light chain) above 40 pg/mL.
- You are able to breathe well, with a lung function test score of at least 65% of normal.
- You have not taken riluzole or edaravone in the last 30 days, or you are on a stable dose for at least 30 days.
- You are willing to travel to the study site for visits and possibly have a PET scan or lumbar puncture.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests a new drug called kamlanoflast for people with ALS whose disease is actively progressing. It aims to see if the drug can slow down the disease by reducing inflammation.
This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.
This trial tests a nasal spray medication, foralumab, to see if it can help people with non-active secondary progressive multiple sclerosis. It is only for people who completed a previous related study (TILS-021).
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.